Non-invasive nose-to-brain delivery system expands treatment options for patients with
SAN JOSE DEL CABO, BAJA CALIFORNIA SUR, MEXICO, August 13,
2026 -- Longevity Medical Institute® today announced the launch
of its Regenerative Neurological Therapy Program, featuring an
advanced intranasal delivery platform designed to transport regenerative
therapies toward the brain through the nasal cavity. The technology expands the
institute's comprehensive neurological program by offering patients a
non-invasive alternative to intrathecal administration for selected
neurological conditions.
The human brain is protected by the blood-brain barrier, a highly selective membrane
that prevents many therapeutic compounds from reaching the central nervous
system. While intrathecal administration remains the most direct route for
delivering regenerative therapies into the cerebrospinal fluid, it requires a
lumbar puncture. The newly launched intranasal platform utilizes one of the
most extensively studied nose-to-brain delivery technologies described in the
scientific literature, allowing physicians to offer a less invasive treatment
option when clinically appropriate.
Unlike conventional nasal sprays, which deposit most of their contents in the
lower nasal passages, the specialized delivery system is engineered to target
the upper nasal cavity near the olfactory region. Research has demonstrated
that compounds delivered to this region may travel toward the brain along the
olfactory and trigeminal nerve pathways, bypassing much of the blood-brain
barrier.
"Neurological regenerative medicine is rapidly advancing, but delivering
therapies to the brain has always been one of the greatest challenges,"
said Dr. Kirk Sanford, Founder and CEO of Longevity Medical
Institute®. "By adding this specialized intranasal delivery
platform, we're expanding our ability to personalize treatment. Patients now
have access to both intrathecal and non-invasive intranasal administration,
allowing our physicians to select the most appropriate delivery method based on
the patient's diagnosis, clinical findings, and treatment goals."
Rather than relying on a traditional spray pump, the system uses an
electronically controlled nebulizer that generates microscopic aerosol droplets
delivered gradually over several minutes. This controlled delivery is designed
to increase contact time within the olfactory region, reduce medication loss
into the throat, and improve delivery consistency, all factors that may support
nose-to-brain transport.
At Longevity Medical Institute®, the platform is used exclusively
for regenerative therapies, including mesenchymal stem cells (MSCs), MSC-derived exosomes,
and selected therapeutic peptides. Treatment recommendations are individualized
by the institute's multidisciplinary team of physicians after a comprehensive
neurological evaluation that may include advanced imaging, laboratory testing,
neurological examination, and review of the patient's medical history.
Human clinical research evaluating MSCs and MSC-derived exosomes has reported
encouraging findings across several neurological conditions, including ischemic
stroke, multiple sclerosis, amyotrophic lateral sclerosis (ALS), spinal cord
injury, Parkinson's disease, Alzheimer's disease, traumatic brain injury,
cerebral palsy, and other neurodegenerative disorders. Across published
studies, researchers have consistently reported a favorable safety profile
while investigating potential improvements in neurological function, disease
stabilization, walking ability, cognitive performance, quality of life, and
neuroinflammation.
"While regenerative neurology continues to evolve through ongoing clinical
research, the published human evidence supporting the safety of MSC-based
therapies is encouraging," added Dr. Sanford. "Our philosophy is to
combine the strongest available scientific evidence with advanced diagnostics
and physician-guided treatment planning, ensuring every recommendation is
tailored to the individual patient."
The addition of the intranasal platform further strengthens Longevity Medical
Institute's comprehensive neurological program, which also includes intravenous
regenerative therapies, intrathecal administration performed in the institute's
fully licensed operating room when indicated, hyperbaric oxygen therapy,
advanced neurological imaging, and multidisciplinary physician care.
As with all regenerative therapies offered by Longevity Medical Institute®,
treatment recommendations are based on physician evaluation, published
scientific evidence, patient-specific factors, and clinical judgment. Although
larger randomized clinical trials are still needed to further define which
patients are most likely to benefit and the durability of treatment responses,
regenerative neurological therapies continue to represent one of the
fastest-growing areas of translational medicine.
For more information about Longevity Medical Institute's Regenerative
Neurological Therapy Program, visit www.longevity-institute.com.
About Longevity Medical Institute®
Longevity Medical Institute® is a physician-led regenerative
medicine and diagnostics center in San José del Cabo, Mexico, dedicated to
advancing evidence-based longevity and regenerative medicine. The institute
combines advanced imaging, comprehensive laboratory diagnostics, physician
specialists, and research-supported regenerative therapies to deliver
personalized care across orthopedics, neurology, cardiovascular medicine,
metabolic health, aesthetics, and healthy aging. Through its commitment to
clinical excellence and scientific research, Longevity Medical Institute® continues
to help define the future of regenerative medicine.
